
Tyler Michael Seibert MD PhD
Central Nervous System Cancer, Urologic Cancer
Radiation Oncology at UC San Diego
Join to View Full Profile
9500 Gilman Dr.MC 0861La Jolla, CA 92093
Phone+1 858-657-7000
Fax+1 858-822-5568
Dr. Seibert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tyler Seibert, MD, PhD is a Radiation Oncologist based in La Jolla, CA with subspecialty practice in Urologic Cancers and Brain Tumors. He completed residency at the University of California San Diego in Radiation Oncology. He holds a Ph.D. in Bioengineering and an M.D., both from the University of California San Diego School of Medicine. Dr. Seibert has extensive experience in treating prostate cancer and gliomas, as well as in predictive genetic testing, advanced MRI, and stereotactic radiotherapy. He has many published research articles to his credit and leads several clinical trials. More information can be found at SeibertLab.com.
Education & Training
University of California (San Diego) Medical CenterResidency, Radiation Oncology, 2014 - 2018
Scripps Mercy HospitalInternship, Transitional Year, 2013 - 2014
University of California San Diego School of MedicineClass of 2013, M.D.
University of California San Diego School of MedicineClass of 2011, Ph.D., Bioengineering
Certifications & Licensure
CA State Medical License 2015 - 2027
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Medical Scientist Training Program National Institutes of Health, 2006-2013
- Biology Fellow Howard Hughes Medical Institute, 2005
Clinical Trials
- Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Start of enrollment: 2020 Dec 29
Publications & Presentations
PubMed
- Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical T...Nikita Sushentsev, Anne Y Warren, Richard Colling, Clare Verrill, Ekaterina Pazukhina
JAMA Oncology. 2025-10-16 - Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men.Taylor B Crawford, Tyler Nelson, Roshan Karunamuni, Heena Desai, Ryan Hausler
Journal of the National Comprehensive Cancer Network. 2025-09-15 - Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.Mariluz Rojo Domingo, Deondre D Do, Christopher C Conlin, Aditya Bagrodia, Tristan Barrett
The Journal of Urology. 2025-09-01
Press Mentions
The Pros and Cons of PSA Tests for Prostate Cancer for Midlife and Older MenMay 21st, 2025
Escalated ADT Falls Short in Men with High-Risk Features After ProstatectomyFebruary 18th, 2023
Polygenic Hazard Score Could Be Effective for Predicting Genetic Risk of Lethal Prostate CancerOctober 31st, 2022- Join now to see all
Grant Support
- RSNA Research Resident/Fellow GrantRSNA Research & Education Foundation2015–Present
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









